Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 for lung involvement in hospitalized COVID-19 patients with impaired breathing
RBR-59447vnPhase 2Completed
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of resomelagon in coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) (3 arms), sponsored by Universidade Federal de Minas Gerais. Started Dec 2020; status: completed.
02
Drugs
resomelagon
03
Conditions
coronavirus disease 2019 (COVID-19)severe acute respiratory syndrome (SARS)
Beyond the preview
Go deeper on RBR-59447vn.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-59447vn.